HomeMarket News Cantor Fitzgerald Takes Bullish Stance on...

Cantor Fitzgerald Takes Bullish Stance on Organogenesis Holdings Cantor Fitzgerald Takes Bullish Stance on Organogenesis Holdings

Actionable Trade Ideas

always free

Bull market. Golden bull in front of laptop with stock charts. Financial investment and trading concept.


Cantor Fitzgerald has initiated coverage of Organogenesis (NASDAQ:ORGO) with an overweight rating, citing attractive valuation and the company’s highly differentiated technology portfolio.

Viewing the estimated $24B advanced wound care and surgical/sports medicine markets favorably, Cantor sees Organogenesis’s offerings as β€œdifferentiated and protected given their strong clinical data,” further noting that it was the only company to have an FDA PMA for both venous leg ulcers and diabetic foot ulcers.

Speaking candidly, Cantor revealed, β€œWe estimate a return to growth in 2024 as the company works to regain customers that were β€˜lost’ during the period of reimbursement confusion.”

The investment bank set a price target of $5 for the stock.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.